论文部分内容阅读
目的研究射频消融(RFA)联合化疗治疗肝转移瘤的临床疗效和应用价值。方法选择不能或不愿手术的肝转移瘤患者46例,共110个病灶,先行射频消融治疗后予4～6周期全身化疗,以患者肿瘤灭活率、局部复发率、生存期及1、2、3年总生存率作为评价指标。结果射频消融后一周复查彩色超声多普勒血流显像(CDFI)及CT增强扫描,肿瘤灭活率93.6%。全部病例经6～50个月随访,局部复发率为10%,中位生存期为31个月,而中位无进展生存期为10.9个月,1、2、3年总生存率为86.9%、58.7%、34.8%。结论射频消融联合化疗治疗肝转移瘤疗效好、并发症少,是治疗肝转移瘤安全、有效的综合治疗方法 。
Objective To study the clinical effect and application value of radiofrequency ablation (RFA) combined with chemotherapy in the treatment of liver metastases. Methods Forty-six patients with metastatic liver tumors who could not or did not want surgery were enrolled. A total of 110 lesions were treated with systemic radiotherapy 4 to 6 weeks after radiofrequency catheter ablation. The rates of tumor inactivation, local recurrence, , 3-year overall survival rate as an evaluation index. Results One week after radiofrequency ablation, color Doppler flow imaging (CDFI) and CT enhanced scanning were performed. The tumor inactivation rate was 93.6%. All cases were followed up for 6 to 50 months. The local recurrence rate was 10%, the median survival time was 31 months, and the median progression-free survival time was 10.9 months. The overall survival rate at 1, 2 and 3 years was 86.9% , 58.7%, 34.8%. Conclusion Radiofrequency ablation combined with chemotherapy for liver metastases has good curative effect and less complications, which is a safe and effective comprehensive treatment for liver metastases.